---
figid: PMC9485632__fphar-13-939780-g005
figtitle: Muscarinic receptor M3 activation promotes fibrocytes contraction
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC9485632
filename: fphar-13-939780-g005.jpg
figlink: /pmc/articles/PMC9485632/figure/F5/
number: F5
caption: Proposed signalling pathway for COPD fibrocytes stimulated with cholinergic/muscarinic
  agonists. Muscarinic M3 receptor activation leads to intracellular Ca2+ increase
  via emptying of endoplasmic reticulum (ER) stores as well as secondary extracellular
  Ca2+ uptake (store-operator calcium entry). Cytosolic Ca2+ rise leads to acto-myosin
  dimerization via myosin light chain kinase (MLCK) activation, thus leading to cell
  contraction. These processes are inhibited at the receptor level by tiotropium bromide
  (M2/M3 antagonist) use, at the endoplasmic reticulum level by thapsigargin use and
  at the contraction level by blebbistatin use. Created with BioRender.com.
papertitle: Muscarinic receptor M3 activation promotes fibrocytes contraction.
reftext: Pauline Henrot, et al. Front Pharmacol. 2022;13:939780.
year: '2022'
doi: 10.3389/fphar.2022.939780
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.
keywords: fibrocyte | COPD | M3 | cholinergic | contraction
automl_pathway: 0.9607248
figid_alias: PMC9485632__F5
figtype: Figure
redirect_from: /figures/PMC9485632__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9485632__fphar-13-939780-g005.html
  '@type': Dataset
  description: Proposed signalling pathway for COPD fibrocytes stimulated with cholinergic/muscarinic
    agonists. Muscarinic M3 receptor activation leads to intracellular Ca2+ increase
    via emptying of endoplasmic reticulum (ER) stores as well as secondary extracellular
    Ca2+ uptake (store-operator calcium entry). Cytosolic Ca2+ rise leads to acto-myosin
    dimerization via myosin light chain kinase (MLCK) activation, thus leading to
    cell contraction. These processes are inhibited at the receptor level by tiotropium
    bromide (M2/M3 antagonist) use, at the endoplasmic reticulum level by thapsigargin
    use and at the contraction level by blebbistatin use. Created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - mats
  - Act5C
  - sqh
  - Mhc
  - Mlc2
  - zip
  - SERCA
  - norpA
  - sl
  - Plc21C
  - Strn-Mlck
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - SGMS1
  - MOB2
  - MOB3A
  - MOB3B
  - MOB3C
  - MOB4
  - MOB1A
  - MOB1B
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - MYH14
  - MYO6
  - MYO10
  - MYO16
  - MYO19
  - MYH1
  - MYH10
  - MYH11
  - MYH13
  - MYH15
  - MYH16
  - MYH2
  - MYH3
  - MYH4
  - MYH6
  - MYH7
  - MYH7B
  - MYH8
  - MYH9
  - MYO1A
  - MYO1B
  - MYO1C
  - MYO1D
  - MYO1E
  - MYO1F
  - MYO1G
  - MYO1H
  - MYO3A
  - MYO3B
  - MYO5A
  - MYO5B
  - MYO5C
  - MYO7A
  - MYO7B
  - MYO9A
  - MYO9B
  - MYO15A
  - MYO15B
  - MYO18A
  - MYO18B
  - MYL1
  - MYL3
  - MYL4
  - MYL6
  - MYL6B
  - MYL10
  - MYL12A
  - MYL12B
  - MYL2
  - MYL5
  - MYL7
  - MYL9
  - MYL11
  - ATP2A1
  - ATP2A2
  - ATP2A3
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - MYLK
  - MYLK2
  - MYLK3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
---
